Strategic Alliances
Nucleus values synergies. Partners can form strategic alliances with any of the Nucleus entities through data/content distribution and customer activation.
Pioneering Mental Wellness
Nucleus is a venture studio creating transformative brands and technologies that are reshaping mental healthcare for millions worldwide.
About Nucleus
Nucleus is a venture studio that launches, acquires, and partners with assets that create meaningful connections between people and the wellness industry.
At the core of everything we do is Neuly—our proprietary data platform that powers all Nucleus brands. This centralized approach allows us to build, scale, and connect our portfolio companies with unprecedented efficiency.
Each spoke in our ecosystem serves a unique purpose: from research and education to clinical tools and consumer platforms. Together, they form a comprehensive network addressing every stakeholder in the mental wellness space.
Our Pillars
Nucleus values synergies. Partners can form strategic alliances with any of the Nucleus entities through data/content distribution and customer activation.
Via Nucleus's API, third parties can leverage industry data and connect their own data to our proprietary technology to offer even more insights for users.
Through our public-facing entities, Nucleus aspires to help people connect and build on top of its ecosystem, creating lasting impact.
The Founding Story
In April of 2021, we co-founded Iter Investments—a venture capital fund investing in companies focused on psychedelic medicine. Our investment team realized very quickly that within the industry there was a lack of connection between the "industry" and "the people."
We saw this gap as a major hindrance to the progression of psychedelics and their foreseeable impact on billions of lives. This is where Nucleus comes in.
Nucleus was founded as a venture studio that launches, acquires, or partners with assets that create the much-needed connection between the people and the industry.
"At Nucleus, we envision a world with unobstructed access to the most effective models of care."
The Nucleus Team
Meet the crew behind Nucleus — exploring the frontier of mental wellness together.
Dustin RobinsonCo-Founder, Nucleus
Logan LenzCo-Founder & CEO
Robert VelardeCo-Founder, Nucleus
Sydney AlcalaPlatform Engineer
Bruce EckfeldtContent Producer
Sam BaumMarketing and Events
Mabel Nash GreenbergContent Producer
Vsevolod DoroshenkoSystems Engineer
Adam TuberoContent Producer
Michelle Weiner, DO MPHClinical Lead
Dr. Scott Fisher, MDPsychiatric Lead
Edgar Asebey, ESQFDA Lead
John Gregg, MBA, CLPFDA Lead
David Wood, ESQ, PHDIntellectual Property Lead
Rayyan ZafarResearch Lead
Andrew Hall, PHDScientific Lead
Matt SavarickTech LeadOur Ventures
Our ecosystem of ventures spans data infrastructure, clinical tools, education platforms, and consumer wellness brands.
The data and technology hub powering the entire Nucleus ecosystem. Advanced analytics, patient management, and clinical intelligence for the psychedelic medicine industry.
Clinical trial management platform streamlining research operations for psychedelic medicine studies.
Premier financial intelligence platform for the psychedelic sector. Market data, investment research, and industry analysis.
Marketing and brand acceleration studio helping psychedelic companies reach their audiences with precision.
matterEducation platform training the next generation of psychedelic practitioners and facilitators.
Smart AI platform for peptides, providing intelligent insights and personalized recommendations for wellness optimization.
Our Approach
We don't just invest. We build, operate, and scale companies that address critical gaps in the psychedelic medicine value chain.
We identify unmet needs in the industry and rapidly prototype solutions with embedded domain experts and clinicians.
Our in-house team of engineers, designers, and operators bring concepts to market with exceptional speed and quality.
Portfolio companies benefit from shared infrastructure, cross-promotion, and our extensive industry network.
Get exclusive updates on our portfolio companies, industry insights, and opportunities to participate in the psychedelic renaissance.